CMS today released a formal guidance that outlines the federal payer’s approach to calculating budget neutrality for Medicaid section 1115 demonstration projects, “to strengthen fiscal accountability.”
CMS today released a formal guidance that outlines the federal payer’s approach to calculating budget neutrality for Medicaid section 1115 demonstration projects, “to strengthen fiscal accountability.”
Medicaid section 1115 provides an avenue for states to waiver from federal rules and test innovative approaches. A recent example of such a project would be the 5-year Medicaid work requirements launched earlier this year.
CMS approves section 1115 projects only if they are budget neutral for the federal government, which ensures limited federal fiscal exposure in Medicaid. This makes budget neutrality a vital consideration in CMS’ negotiations with states over specific terms prior to launching a demonstration project. Projects are subject to a budget neutrality test, subsequent to which limits are placed on a state’s federal funding for the period of the project.
Read more about Medicaid work requirements.
Alluding to the fact that federal spending on the demonstration projects had grown by more than $100 billion between 2013 and 2016, CMS Administrator Seema Verma said, “Today’s guidance is a comprehensive explanation of how CMS and our state partners can ensure that new demonstration projects can simultaneously promote Medicaid’s objectives and keep federal spending under control.”
Budget neutrality calculation requires use of the baseline or without waiver (WOW) expenditures. WOW is based on every eligible member’s spending per month. The per member per month (PMPM) approach shields the state from the risk for increased costs that are linked with increased enrollment, neither does it accrue savings from reduced enrollment. Multiplying the projected WOW PMPM costs with the monthly caseload is the estimated PMPM expenditure limit.
CMS has also provided state Medicaid directors direction on calculating budget neutrality expenses for demonstration extensions. This includes a comprehensive review of the expenditure in the prior demonstration period to ensure reporting accuracy, followed by any necessary adjustments to changes in waivers and expenditure authorities under the extension. To limit federal Medicaid spending, CMS implemented policies such as limited savings rollover and rebasing WOW baselines.
States will be provided a new monitoring tool that consolidates financial data for all demonstration projects to streamline reporting and avoid redundancy, to be uploaded to the Performance Metrics Database & Analytics system, which states currently use for their other reports.
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More